跳至主要内容
临床试验/NCT01418066
NCT01418066已完成不适用

Feasibility and Safety of Ayurvedic Herbs in Diarrhoea-predominant Irritable Bowel Syndrome

Universität Duisburg-Essen1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2011年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
32
试验地点
1
主要终点
irritable bowel syndrome- symptom severity score

研究概览

简要总结

In the present study the investigators are trying to evaluate the effect of Murraya koenigii leaves, Punica granatum and Curcuma which is administered to the patients in a combined form as tea. This study will help to evaluate the effect of these preparations scientifically in improving the IBS symptoms.

详细描述

see above

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Irritable Bowel Syndrome according to Rom-III
  • Subtype Diarrhea or Alternating
  • discomfort or pain > 1 times a week
  • discomfort or pain > 4 on a Visual Analog Scale

排除标准

  • Inflammatory bowel diseases (test results necessary)
  • Lactose, Fructose Malabsorption (test results necessary)
  • Celiac Disease
  • Pregnancy or Breastfeeding
  • Colectomy or Hemicolectomy >50cm
  • Severe metabolic disorders, hormonal disorders, cardiac or respiratory failure, liver or renal diseases
  • severe depression, psychotic or psychiatric disorders, substance abuse
  • cancer within the last 5 years
  • allergy to caraway
  • acute inflammatory diseases

研究组 & 干预措施

Placebo

Placebo Comparator

Tea decoction made of Graminis Flores abd Maidis stigmata.

干预措施: Placebo tea (Drug)

Ayurvedic herbs

Experimental

Tea decoction made of Murraya koenigii leaves, Punica granatum and Curcuma

干预措施: Ayurvedic Herbs (Drug)

结局指标

主要结局

irritable bowel syndrome- symptom severity score

时间窗: T2 (Day 28)

IBS-SSS(Francis, 1997)

次要结局

  • Frequency of abdominal discomfort/Pain(last week of treatment (days 21-28))
  • Intensity of Abdominal Pain/Discomfort(Last week of treatment (days 21-28))
  • Stool and diarrhea Frequency(last week of treatment (days 21-28))
  • Quality of life(T2 (Day 28))
  • IBS Specific Quality of life(T2 (Day 28))
  • Depression and Anxiety(T2 (day 28))
  • Adequate Relief Score(at day 7, 14, 21 and 28)
  • Global improvement(at days 7, 14, 21 and 28)
  • adverse events(up to week 15)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jost Langhorst

Prof. Dr.

Universität Duisburg-Essen

研究点 (1)

Loading locations...

相似试验